Critical Care

official impact factor 4.60
Search for
Advanced search
Critical Care
Tools
Share this article

This article is part of the supplement: Severe sepsis and drotrecogin alfa (activated)

Highly Access

Recombinant human activated protein C: current insights into its mechanism of action

Marcel Levi* and Tom van der Poll

Critical Care 2007, 11(Suppl 5):S3 doi:10.1186/cc6154

Accesses  

  • Last 30 days: 49 accesses
  • Last 365 days: 751 accesses
  • All time: 5472 accesses

Cited by

BioMed Central: 4 citations

Research   Open Access Highly Accessed

Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock

Herbert Spapen, Duc Nguyen, Joris Troubleyn, Luc Huyghens, Johan Schiettecatte Critical Care 2010, 14:R54 (7 April 2010)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central

Research   Open Access Highly Accessed

Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort

Richard V Hodder, Richard Hall, James A Russell, Harold N Fisher, Bobbie Lee Critical Care 2009, 13:R78 (20 May 2009)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central

Commentary   Free

Recombinant human activated protein C in acute lung injury: what is the role of bronchial circulation?

Marc O Maybauer, Daniel L Traber, Dirk M Maybauer Critical Care 2009, 13:112 (23 January 2009)

Abstract | Full text | PDF | PubMed

Introduction   Free Highly Accessed

Introduction: severe sepsis and drotrecogin alfa (activated)

Antonio Artigas, Claude D Martin Critical Care 2007, 11(Suppl 5):S1 (19 December 2007)

Full text | PDF | PubMed

Google Scholar: View citations

ISI Web of Science: View citations

PubMed Central: View citations